Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Correction: Metric-based vs peer-reviewed evaluation of a research output: Lesson learnt from UK's national research assessment exercise.

Koya K, Chowdhury G.

PLoS One. 2017 Dec 20;12(12):e0190337. doi: 10.1371/journal.pone.0190337. eCollection 2017.

2.

Artificial DnaJ Protein for protein production and conformational diseases.

Hishiya A, Koya K.

Sci Rep. 2017 Aug 17;7(1):8531. doi: 10.1038/s41598-017-09067-7.

3.

Metric-based vs peer-reviewed evaluation of a research output: Lesson learnt from UK's national research assessment exercise.

Koya K, Chowdhury G.

PLoS One. 2017 Jul 11;12(7):e0179722. doi: 10.1371/journal.pone.0179722. eCollection 2017. Erratum in: PLoS One. 2017 Dec 20;12 (12 ):e0190337.

4.

The embodied nurse: Interdisciplinary knowledge exchange between compassionate nursing and recent developments in embodied leadership studies.

Koya K, Anderson J, Sice P.

J Adv Nurs. 2017 Dec;73(12):3028-3040. doi: 10.1111/jan.13363. Epub 2017 Jul 20.

PMID:
28620966
5.

Measuring the Impact of Research: Lessons from the UK's Research Excellence Framework 2014.

Chowdhury G, Koya K, Philipson P.

PLoS One. 2016 Jun 8;11(6):e0156978. doi: 10.1371/journal.pone.0156978. eCollection 2016.

6.

Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol.

Vo NH, Xia Z, Hanko J, Yun T, Bloom S, Shen J, Koya K, Sun L, Chen S.

J Inorg Biochem. 2014 Jan;130:69-73. doi: 10.1016/j.jinorgbio.2013.10.005. Epub 2013 Oct 12.

PMID:
24176921
7.

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):401-9. doi: 10.1016/j.taap.2013.09.018. Epub 2013 Oct 1.

8.

Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

Chen S, Sun L, Koya K, Tatsuta N, Xia Z, Korbut T, Du Z, Wu J, Liang G, Jiang J, Ono M, Zhou D, Sonderfan A.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5070-6. doi: 10.1016/j.bmcl.2013.07.032. Epub 2013 Jul 25.

PMID:
23937981
9.

YouTube and the expanding role of videos in dermatologic surgery education.

Koya KD, Bhatia KR, Hsu JT, Bhatia AC.

Semin Cutan Med Surg. 2012 Sep;31(3):163-7. doi: 10.1016/j.sder.2012.06.006.

PMID:
22929353
10.

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.

Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, Beaudette-Zlatanova BC, Lu R, Blackman RK, Barsoum J, Koya K, Wada Y.

Free Radic Biol Med. 2012 May 15;52(10):2142-50. doi: 10.1016/j.freeradbiomed.2012.03.017. Epub 2012 Apr 17.

PMID:
22542443
11.

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y.

Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10.

12.

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

13.

Mortalin inhibition in experimental Parkinson's disease.

Chiasserini D, Tozzi A, de Iure A, Tantucci M, Susta F, Orvietani PL, Koya K, Binaglia L, Calabresi P.

Mov Disord. 2011 Aug 1;26(9):1639-47. doi: 10.1002/mds.23647. Epub 2011 May 3.

PMID:
21542017
14.

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK.

PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.

15.

Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.

Pilzer D, Saar M, Koya K, Fishelson Z.

Int J Cancer. 2010 Mar 15;126(6):1428-35. doi: 10.1002/ijc.24888.

16.

Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines.

James DA, Koya K, Li H, Liang G, Xia Z, Ying W, Wu Y, Sun L.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1784-7. doi: 10.1016/j.bmcl.2008.02.029. Epub 2008 Feb 16.

PMID:
18308566
17.

Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines.

James DA, Koya K, Li H, Chen S, Xia Z, Ying W, Wu Y, Sun L.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5164-8. Epub 2006 Jul 25.

PMID:
16870446
18.

Determination of MKT-077, a novel antineoplastic agent, in plasma samples by high-performance liquid chromatography and its application to pharmacokinetics in rats.

Tatsuta N, Suzuki N, Koya K, Kawakami M, Shishido T, Chen LB.

J Pharm Biomed Anal. 1999 Mar;19(3-4):423-8.

PMID:
10704107
19.

Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.

Tatsuta N, Suzuki N, Mochizuki T, Koya K, Kawakami M, Shishido T, Motoji N, Kuroiwa H, Shigematsu A, Chen LB.

Cancer Chemother Pharmacol. 1999;43(4):295-301.

PMID:
10071980
20.

Selective antitumor activity of MKT-077, a delocalized lipophilic cation, on normal cells and cancer cells in vitro.

Chiba Y, Kubota T, Watanabe M, Otani Y, Teramoto T, Matsumoto Y, Koya K, Kitajima M.

J Surg Oncol. 1998 Oct;69(2):105-10.

PMID:
9808514
21.

MKT-077, localized lipophilic cation: antitumor activity against human tumor xenografts serially transplanted into nude mice.

Chiba Y, Kubota T, Watanabe M, Matsuzaki SW, Otani Y, Teramoto T, Matsumoto Y, Koya K, Kitajima M.

Anticancer Res. 1998 Mar-Apr;18(2A):1047-52.

PMID:
9615763
22.

Structure-activity of novel rhodacyanine dyes as antitumor agents.

Kawakami M, Koya K, Ukai T, Tatsuta N, Ikegawa A, Ogawa K, Shishido T, Chen LB.

J Med Chem. 1998 Jan 1;41(1):130-42.

PMID:
9438030
23.

Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077.

Modica-Napolitano JS, Brunelli BT, Koya K, Chen LB.

Cancer Res. 1998 Jan 1;58(1):71-5.

24.

Synthesis and evaluation of novel rhodacyanine dyes that exhibit antitumor activity.

Kawakami M, Koya K, Ukai T, Tatsuta N, Ikegawa A, Ogawa K, Shishido T, Chen LB.

J Med Chem. 1997 Sep 26;40(20):3151-60.

PMID:
9379434
25.

In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function.

Weisberg EL, Koya K, Modica-Napolitano J, Li Y, Chen LB.

Cancer Res. 1996 Feb 1;56(3):551-5.

26.

Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077.

Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, Chen LB.

Cancer Res. 1996 Feb 1;56(3):544-50.

27.

MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.

Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Shishido, Chen LB.

Cancer Res. 1996 Feb 1;56(3):538-43.

28.

[Study on clinical standard consistency of the luting cement].

Nakamura Y, Sato M, Koya K, Noguchi H.

Ou Daigaku Shigakushi. 1989 Nov;16(3):117-23. Japanese.

PMID:
2701261
29.

[Clinical results of ibuprofen suppository (UP-sup) in orosurgical field].

Takai H, Mimamidate K, Suzuki H, Koya K, Sanjo S.

Shikai Tenbo. 1981 Feb;57(2):387-95. Japanese. No abstract available.

PMID:
6943706
30.

[2 CASES OF LEIOMYOSARCOMA OF THE RECTUM].

NAGASU K, NAKANISHI A, ISHIKO T, MUNETA K, KONDO M, KOYA K, ISHIYAMA S.

Nihon Chokucho Komonbyo. 1964 Mar;19:19-20. Japanese. No abstract available.

PMID:
14153543

Supplemental Content

Support Center